What is BuyMed?
Founded in 2018, BuyMed operates as a technology-driven intermediary that bridges the gap between pharmaceutical manufacturers and end-point healthcare providers. The company's core platform serves as an all-in-one B2B ordering application, allowing pharmacies to streamline procurement, compare competitive pricing, and manage inventory through a centralized digital interface. Beyond its B2B infrastructure, the firm has expanded its operational footprint through Circa, a B2C retail network designed to modernize traditional pharmacy operations. By integrating these digital solutions, BuyMed effectively reduces friction in the healthcare ecosystem, ultimately enhancing the quality and accessibility of medical supplies for patients across the region.
How much funding has BuyMed raised?
BuyMed has raised a total of $2.5M across 1 funding round:
Other Financing Round
$2.5M
Other Financing Round (2020): $2.5M with participation from Steamboat Ventures, Genesia Ventures, and Cocoon Capital
Key Investors in BuyMed
Steamboat Ventures
A venture capital firm established in 2000 that specializes in nurturing early to growth-stage companies within the technology, media, and consumer sectors to achieve market leadership.
Genesia Ventures
An investment firm focused on supporting innovative startups through strategic capital and operational guidance to foster long-term growth.
Cocoon Capital
A venture capital firm that provides early-stage funding and hands-on support to high-potential technology companies looking to disrupt traditional industries.
What's next for BuyMed?
With this major enterprise-level funding, BuyMed is poised to scale its digital infrastructure and expand its market reach. The strategic focus will likely center on deepening the integration between its B2B ordering platform and the Circa retail network, creating a cohesive, data-backed supply chain model. As the company matures, it is expected to leverage this capital to forge new partnerships with regional distributors and manufacturers, further solidifying its position as a leader in the digital health sector. The firm's trajectory suggests a transition from early-stage market entry to a phase of aggressive operational scaling and ecosystem dominance.
See full BuyMed company page
